Lipidor AB reports progress in Phase III trial

Lipidor has announced, that 50% of the patients in the ongoing Phase III study for the drug candidate AKP02G2 have now been enrolled. This marks a milestone in the study, and due to an accelerated enrollment as the number of participating clinics grow, the company expects to have the result of the study as soon as in April 2025.
At LSIF we have high expectations to this study due to the clear identification of why the previous study did not meet its endpoint and the subsequent redesign of the new study. In the event of a positive outcome, it is our assessment that the quality of life of many psoriasis patients can be significantly improved, and the potential for Lipidor AB will be very large.